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Background:  Metastatic  disease  of  the spine  is  an  increasingly  common  public  health  problem.  Surgery
should  be  an  integral  component  of the  overall  cancer  treatment  plan  and, importantly,  must  neither
delay  not  jeopardize  any  of  the other  components.  The  prognosis  governs  the  choice  of  the  surgical
strategy.  Tokuhashi  et  al.  developed  a prognostic  score  in  1990, then  revised  it in 2000  and  2005.  Here,
our  objective  was  to evaluate  the  performance  of  the  Tokuhashi  score  in a cohort  of  260  patients  and  to
look for  other  variables  that might  improve  preoperative  outcome  prediction.
Material  and  method:  We  retrospectively  established  a  single-centre  cohort  of  260 patients  who  under-
went  spinal  metastasis  surgery  between  1998  and  2008.  For  each  patient,  the following  data  were
collected  prospectively:  socio-demographic  features,  history  of  the  malignancy,  variables  needed  to
determine  the  Tokuhashi  score,  and  treatments  used.  SAS  9.0  software  was  chosen  for the  statistical
analysis.  Variables  were  described  as  mean  ±  SD, overall  survival  was  estimated  using  the  Kaplan–Meier
method,  and  survivals  in  subgroups  were compared  by  the  log-rank  test. To  assess  agreement  between
survival  predicted  by  the  Tokuhashi  score  and  observed  survival,  we  computed  Cohen’s  kappa  and  inter-
preted  the  results  according  to Landis  and  Koch.
Results: There  were  143  females  and  117  males  with  a  mean  age  of  59  years  and  overall  median  sur-
vival  of 10  months.  Median  observed  survivals  in  the three  Tokuhashi  score  categories  (<  6,  6–12, and
>  12 months  predicted  survival)  were  5, 10,  and  36  months,  respectively.  These  survival  times  differed
signiﬁcantly  (P <  0.0001).  Cohen’s  kappa  indicated  moderate  agreement  between  predicted  and  observed
survivals.  Other  factors  associated  with  signiﬁcant  survival  differences  were  time  from  cancer  diagnosis
to metastasis  diagnosis  (synchronous,  < 2 years, 2–5 years,  or > 5 years;  P < 0.0001)  and  age  (< 70 years  or
≥  70  years,  P  =  0.0053).
Conclusion:  Our cohort  study  supports  the validity  and  reproducibility  of the  Tokuhashi  score.  Our  ﬁnd-
ing  that  shorter  time  to  metastasis  diagnosis  and  age  ≥ 70 years  were  also  signiﬁcantly  associated  with
survival  in our  population  invites  further  efforts  to  improve  and  update  the  Tokuhashi  score.
Level  of evidence:  IV,  retrospective  study.
©  2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Spinal tumours, particularly metastases, constitute an increas-
ngly common public health problem. Among causes of paraplegia,
umours now tend to be at least as common than injuries [1,2].
n addition, the development of a major neurological impairment
ften leads to the discontinuation of cancer treatments.
∗ Corresponding author. Service de neurochirurgie, CHU de Reims, 45, rue
ognacq-Jay, 51100 Reims, France. Tel.: +33 2 36 78 76 59;
ax: +33 3 26 78 40 97.
E-mail address: ceap@chu-reims.fr (C. Eap).
http://dx.doi.org/10.1016/j.otsr.2015.03.007
877-0568/© 2015 Elsevier Masson SAS. All rights reserved.The objectives of spinal metastasis therapy are functional and
include improving quality of life; preventing or improving neu-
rological function, which requires a careful evaluation of the
neurological risk before impairments develop; ensuring stability
of the spine; alleviating the pain; and avoiding the need for exter-
nal immobilisation devices. The overall goal is to allow the patient
to remain self-sufﬁcient and capable of living at home for as long
as possible.
Achieving these objectives requires a multidisciplinary
approach in which the surgeon plays a major role. If surgi-
cal management is deemed appropriate, it must neither delay
nor jeopardise the other components of the cancer treatment
plan.
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The prognosis in each individual patient is a key factor in choos-
ng the best surgical strategy. In 1990, Tokuhashi et al. developed
 score for predicting the outcomes of spinal metastases [3]. They
evised their score in 2000 [4] and 2005 [5]. The score uses six
ariables to classify patients into three prognostic categories with
redicted survival times of less than 6 months, 6 to 12 months, and
ore than 12 months, respectively. The category provides some
easure of guidance for selecting the surgical strategy [5].
Here, our objectives were to evaluate the predictive perfor-
ance of the Tokuhashi score in a cohort of 260 patients and,
mportantly, to look for other factors that further improved out-
ome prediction, thereby providing additional guidance about the
est surgical treatment.
. Material and methods
.1. Patients
We  retrospectively established a cohort of 260 patients who
nderwent spinal metastasis surgery at the neurosurgery depart-
ent of the Foch Hospital, Suresnes, France, between 1998 and
008. Inclusion criteria were age older than 18 years, metastatic
pinal disease requiring surgical treatment (e.g., nerve root or
pinal cord compression, risk of neurological compromise), and
illingness to participate in the study. We  did not include patients
ounger than 18 years of age, under guardianship, or having miss-
ng data. Exclusion criteria were non-metastatic spinal tumours
e.g., primary tumours or spinal involvement with haematological
alignancies), history of spinal biopsy, and intra-dural metastases.
.2. Data collection
We  recorded the following data for each patient: age and gender,
ircumstances of spinal metastasis diagnosis, time from diagno-
is of the primary to diagnosis of the spinal metastases, variables
eeded to compute the 2005 version of the Tokuhashi score [5],
nd characteristics of the treatment (e.g., surgical approach, oper-
tive technique, and preoperative or postoperative radiotherapy).
he data were recorded at the time of death in non-survivors and
0 and 110 months after spinal metastasis surgery in survivors.
.3. Statistical analysis
We  used SAS 9.0. software (SAS Institute, Cary, NC, USA) for
he statistical analyses. Qualitative variables were described as
ean ± SD and qualitative variables as n (%).
Kaplan–Meier curves were plotted to estimate overall survival,
ith the date of spinal metastasis surgery as the starting point and
eath as the end point. Survival across groups was compared using
he log-rank test.We  evaluated the level of agreement between survival predicted
y the Tokuhashi score and observed survival. To this end, we  com-
uted Cohen’s kappa coefﬁcient () [6] and interpreted the results
ccording to Landis and Koch [7].
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3. Results
3.1. Patient population
We  identiﬁed 260 patients, 143 (55%) females and 117 (45%)
males with a mean age of 59 ± 11 years (range, 24–81 years). Table 1
reports the sites of the primary malignancies. For each patient,
the appropriateness of spinal metastasis surgery was  evaluated
in a multidisciplinary meeting. Criteria for palliative surgery were
spinal cord compression; nerve root compression; pain; risk of neu-
rological compromise, most notably related to spinal instability;
and an expectation that spinal surgery would improve the onco-
logical prognosis. Excisional surgery was  considered appropriate
only when a slowly growing solitary spinal metastasis was present
in a young patient. Of our 260 patients, 17 underwent excisional
surgery and 243 palliative surgery.
The surgical approach and operative technique were chosen
based on the vertebral segment involved, number of vertebral
metastases, and general health condition of the patient. Intra-
operative vertebroplasty was performed in 82 (31.5%) patients.
Other procedures were posterior decompression with internal ﬁx-
ation (56%), anterior decompression with internal ﬁxation (37%),
decompression alone (5%) and vertebrectomy (2%).
3.2. Survival predicted by the Tokuhashi score and observed
survival
Overall mean survival was 10 months. Of the 260 patients, 212
(82%) died within 60 months of spinal metastasis surgery.
Table 2 reports the values for each of the Tokuhashi score
items. Patient distribution in the three prognostic groups deﬁned
by the Tokuhashi score was  as follows: score 0–8 (predicted
survival < 6 months), 105 (40.4%) patients; score 9–11 (predicted
survival > 6 months), 82 (31.5%) patients; and score 12–15 (pre-
dicted survival > 12 months), 73 (28.1%) patients.
Table 3 reports predicted and observed survivals. Observed
median survival in the 0–8, 9–11, and 12–15 Tokuhashi score
groups was  5 months (95% CI, 3–6), 10 months (95% CI, 8–19), and
36 months (95% CI, 30–54), respectively. Fig. 1 displays the sur-
vival curves. Survival differed signiﬁcantly across the three groups
(P < 0.0001).
The weighted  computed to assess agreement between survival
predicted by the Tokuhashi score and observed survival was  0.41
(95% CI, 0.33–0.50). According to Landis and Koch [7], this  value
indicates moderate agreement.
We classiﬁed tumour histology according to the system used
for the Tokuhashi score. Table 1 reports the results. Kaplan–Meier
survival estimates differed signiﬁcantly across histological groups
(P < 0.0001).
Median survival differed signiﬁcantly according to the Frankel
grade function (P = 0.0001), as follows: Frankel E, 16 months (95%
CI, 11–25); Frankel C-D, 6 months (95% CI, 4–9); and Frankel A-B,
4 months (95% CI, 1–7). The very short survival in the Frankel A-B
group, which we  believe contra-indicates surgery, emphasises the
importance of preventing neurological impairments and evaluating
the risk of neurological compromise.
Kidney Bladder Other Unidentiﬁed
10% 3% 10% 6%
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Table  2
Tokuhashi item results.
Parameters Tokuhashi score categories Number of patients Median survival (months) 95% CI
General condition: Karnofsky performance status
Poor (10%–40%) 0 31 4 3–9
Moderate (50%–70%) 1 136 9 7–13
Good  (80%–100%) 2 93 22 14–31
Number of extraspinal bone metastases
≥ 3 0 37 8 4–11
2  1 73 10 6–22
1  2 150 11 9–16
Number of spinal metastases
≥  3 0 106 8 5–10
2  1 32 11.5 7–24
1  2 122 14 10–25
Metastases to major internal organs
Inoperable 0 89 5 4–9
Operable 1 23 26 11–40
None  2 148 16 10–26
Primary cancer
Lung, osteosarcoma, stomach, bladder, oesophagus, pancreas 0 69 5 4–8
Liver,  gallbladder, unidentiﬁed 1 17 4 1–10
Other  2 13 9 5–30
Kidney, uterus 3 29 9 4–11
Rectum 4 11 5 2–10
Thyroid, breast, prostate, carcinoid tumour 5 121 31 24–38
Palsy: Frankel grade
Complete (A, B) 0 9 4 1–7
Incomplete (C, D) 1 72 6 4–9
None  (E) 2 179 16 11–25
95% CI: 95% conﬁdence interval.
Fig. 1. Kaplan–Meier survival curves in the categories deﬁned by the Tokuhashi score values.
Table 3
Observed survival versus survival predicted by the Tokuhashi score.
Observed survival < 6 months 6–12 months > 12 months
Tokuhashi predicted survival
<6 months (group 1) 57 (54.3%) 29 (27.6%) 19 (18.1%)
6–12 months (group 2) 25 (30.5%) 18 (21.9%)a 39 (47.6%)a
57 (69.5%)a
>12 months (Group 3) 4 (5.5%) 6 (8.2%) 63 (86.3%)
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Table 4
Other parameters studied.
Parameters Number of
patients
Median
survival
95% CI
Age
< 50 years 48 19 11–30
50–60 years 88 10 8–21
60–70 years 75 9 8–20
>  70 years 49 7 3–11
Time from diagnosis of primary to
diagnosis of spinal metastases
Synchronous 79 9 5–10
0–2  years 56 6 5–10
2–5  years 66 21 9–30
>  5 years 59 24 13–40
Operated spinal segment
Cervical 41 19 8–29
Cervical-thoracic 9 10 6–25
Thoracic 144 9 7–11
Thoracolumbar 10 6.5 3–45
Lumbar 53 22 9–36
Sacro-lumbar 2 6 3–9
Sacral 1 10a In group 2, 69.5% of patients survived longer than 9 months.
.3. Identiﬁcation of additional predictors of survival
We  separately evaluated the potential association with sur-
ival of the parameters listed in Table 4. As illustrated by Fig. 2,
ge ≥ 70 years was associated with signiﬁcantly shorter survival
P = 0.0053). Although not among the Tokuhashi score items, age
s, in our opinion, a major consideration when making surgical
ecisions in everyday practice and should be factored into the pre-
perative evaluation.
The time in months from diagnosis of the primary to diag-
osis of spinal metastatic disease was available for all patients.
e converted this continuous variable into four categories, as
95% CI: 95% conﬁdence interval.
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Fig. 2. Kaplan–Meier survival curves in patients < 70 years versus ≥ 70 years of age.
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bFig. 3. Kaplan–Meier survival curves in grou
ollows: 0 (n = 79, 30.4%), ≤ 2 years (n = 56, 21.5%%), 2–5 years
n = 66, 25.4%), and > 5 years (n = 59, 22.7%). Survival as assessed
sing Kaplan–Meier curves differed signiﬁcantly across these four
roups (log-rank test, P < 0.0001) (Fig. 3).
Table 4 lists the spinal segments involved. Comparison of
urvival curves across the seven groups failed to detect any signif-
cant difference (log-rank test, P = 0.29). Thus, the spinal segment
nvolved with metastatic disease does not affect survival. Never-
heless, the site of the metastasis inﬂuences the risk of neurological
ompromise and the feasibility of surgical treatment. For instance,
ith metastases in the cervical spine, the major risk of severe
eurological compromise and ease of access, particularly via the
nterior approach, encourage an aggressive surgical strategy. Chal-
enges raised by ensuring spinal stability are greatest at the
unctions, most notably between the cervical and thoracic spine.
. Discussion
The surgical management of spinal metastases has been the
ocus of much controversy. In a 1979 prospective randomised trial
level 1 evidence) by Young and Feldman, 16 patients managed
ith radiotherapy and laminectomy had no signiﬁcant outcome
ifferences compared to 13 patients managed with radiotherapy
lone [8]. Despite the small numbers of patients in both groups and
he short follow-up of only 4 months, this trial generated a strong
elief that surgery was unhelpful in spinal metastases. Since then,
any small case-series studies have suggested beneﬁcial effects
f surgery. However, not until 2005 was a new prospective ran-
omised trial reported, by Patchell et al., who studied 123 patients
istributed into two comparable groups [9]. The trial was  stopped
rematurely when an interim analysis showed signiﬁcantly better
utcomes with combined surgery and radiotherapy compared to
adiotherapy alone.
Accurate outcome prediction is crucial for determining the
est surgical strategy in patients with spinal metastases. Also ofﬁned by time to spinal metastasis diagnosis.
importance are the beneﬁts expected by the patient and the risk
of complications, as postoperative complications can cause rapid
deterioration in these fragile patients [10–12]. Survival in patients
with spinal metastases has therefore been the focus of numerous
studies, which produced variable results. In a 1996 report by Tatsui
et al. of patients with spinal metastatic disease diagnosed by bone
scintigraphy, 1-year survival varied across primary tumour sites,
as follows: 83.3% for prostate cancer, 77.7% for breast cancer, 51.2%
for kidney cancer, 21.7% for lung cancer, and 0% for stomach cancer
[13].
Major strengths of our study include the large sample size
(n = 260) and 10-year follow-up. We  found no previously published
studies of larger populations with surgically treated spinal metas-
tases. No selection bias occurred, as we included all patients who
underwent spinal metastasis surgery in our department during the
study period. Although the data were analysed retrospectively, they
were collected prospectively.
Our results support the validity of the Tokuhashi score for pre-
dicting outcomes in patients with spinal metastases. The level of
agreement between outcomes predicted based on the Tokuhashi
score and observed outcomes were moderate, as assessed accord-
ing to Landis and Koch. We  believe this level of agreement is largely
satisfactory in clinical practice.
We obtained two  unexpected results. First, median survival was
longer in patients with inoperable internal organ metastases than
in patients with no internal organ metastases (Table 1). Two factors
may  explain this ﬁnding, namely, the small number of patients with
internal organ metastases (n = 23) and the predominance among
them of primaries associated with long survival times (breast can-
cer, n = 14; prostate cancer, n = 4; lung cancer, n = 2; stomach cancer,
n = 1; urinary bladder cancer, n = 1; and other, n = 1). Second, sur-
vival was short among patients with metastases from rectal cancer.
This result may  be ascribable to the small number of patients in this
subgroup (n = 11).
The Tokuhashi score was ﬁrst reported in 1990 [3], then used,
analysed, and validated in several studies [12,14–16]. Neurological
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mpairments had no adverse prognostic signiﬁcance in some
tudies [17,18]. Nevertheless, our patients with neurological
mpairments had signiﬁcantly worse outcomes, in keeping with a
tudy of 200 patients reported by Arrigo et al. [19]. In 1997, Enkaoua
t al. suggested changing the number of points for metastases from
nidentiﬁed primaries from 1 to 0 [20]. Our ﬁndings support this
uggestion.
In 2001, Tomita et al. reported another scoring system based
n three prognostic factors: grade of the malignancy, number and
reatability of visceral metastases, and number of bone metas-
ases [17]. Their rationale for developing a new score was  that the
okuhashi score distinguishes only two treatment options, exci-
ional and palliative surgery, instead of considering the full range
f currently available surgical strategies.
Two 2007 reports by Ulmar et al. assess the Tokuhashi [16] and
omita [21] scores in a cohort of 217 patients with vertebral metas-
ases. Their results validate the Tokuhashi score and establish its
uperiority over the Tomita score for predicting survival. Similarly,
n 2013, Quraishi et al. reported that the Tokuhashi score provided
aluable guidance for surgical decision-making [12].
We  believe the Tokuhashi score alone is not sufﬁcient to select
atients for excisional surgery. The appropriateness of excisional
urgery should be discussed in a multidisciplinary meeting based
n a range of characteristics including age and tumour aggres-
iveness. Of our 260 patients, 17 underwent excisional surgery.
heir median survival was 84 months (95% CI, 41–96). Palliative
urgery was performed in 243 patients, whose median survival was
 months (95% CI, 8–11). The survival curves differed signiﬁcantly
etween these two groups (P < 0.0001).
Patient age at surgery emerged as a major prognostic factor. As
 corollary to the ageing of the general population, age at manage-
ent tends to increase. Thus, surgeons are increasingly assessing
lderly patients referred for the management of spinal metastases.
n a study by Arrigo et al. [19], age was a signiﬁcant predictive fac-
or when incorporated into the Charlson Comorbidity Index [22],
ut not when considered alone. In our study, age ≥ 70 years was
igniﬁcantly associated with shorter survival.
Another important prognostic factor in our study was the
ime from the diagnosis of the primary to the diagnosis of spinal
etastatic disease. According to the log-rank test, survival times
iffered signiﬁcantly (P < 0.0001) across the four primary to metas-
asis interval groups distinguished in our study (synchronous,
 2 years, 2–5 years, and > 5 years). The Kaplan–Meier analysis also
ndicated markedly shorter survival times among patients with
arly metastases. These ﬁndings conﬁrm the poor prognostic sig-
iﬁcance of early metastases. In contrast, patients with delayed
etastatic disease deserve to be considered for more radical exci-
ional procedures.
Patients with synchronous metastases had longer survival times
ompared to those with metastases diagnosed within 2 years of the
rimary in our study. This ﬁnding is clearly ascribable to the good
rognosis of the primaries responsible for synchronous metastases,
hich responded well to systemic therapy. In contrast, patients
iagnosed with metastases disease within the ﬁrst 2 years devel-
ped these tumours despite systemic treatment for the primary.
ur data support the importance in everyday practice of the time
o metastasis diagnosis when selecting the surgical strategy.
Our ﬁndings conﬁrm the validity of the Tokuhashi score as a
rognostic tool for patients with spinal metastases, in agreement
ith earlier studies. Nevertheless, we believe the Tokuhashi score
hould be updated by adding variables, such as age ≥ 70 years and
ime to metastasis diagnosis, which were signiﬁcantly associated
ith survival in our study. The steady pace of progress in the
herapeutic weaponry available for cancer treatment requires reg-
lar reappraisals of prognostic tools. Non-operative treatments are
ncreasingly used in a targeted manner, most notably according to
[urgery & Research 101 (2015) 483–488 487
the histological tumour type. The histological classiﬁcation used in
the Tokuhashi score may  now appear simplistic. Among surgical
procedures, percutaneous internal ﬁxation techniques developed
to treat spinal injuries have a broad range of applications in spinal
metastasis surgery. For instance, minimally invasive stabilisation
procedures can be used for patients who  are not candidates for open
palliative surgery. Although few published data are available on this
point, we  believe that percutaneous techniques have a role to play
in spinal metastasis surgery [23]. Finally, stereotactic radiotherapy
of the spine is developing at a brisk pace. This method allows the
delivery of higher doses to the tumour while sparing the adjacent
structures, such as the nervous system [24–26], a property that
would be expected to optimise post-radiotherapy outcomes.
This array of recent advances offers hope for improving patient
outcomes and supports the need for studies aimed at optimising
current prognostic scores.
5. Conclusion
Our cohort study conﬁrms the validity and reproducibility
of the Tokuhashi score for outcome prediction in patients with
spinal metastatic disease. Nevertheless, two  additional variables,
age ≥ 70 years and time to metastasis diagnosis, were signiﬁcantly
associated with survival in our population. These variables deserve
to be incorporated into tools designed to predict outcomes in
patients with spinal metastases.
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